WATCH LIVE
timothy sykes logo
RLMD Jumps As HC Wainwright Launches Buy Coverage Thumbnail
G Google News

RLMD Jumps As HC Wainwright Launches Buy Coverage

TIM SYKES•UPDATED JUN. 26, 2026, 4:38 PM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Relmada Therapeutics Inc. stocks have been trading up by 3.72 percent, driven by optimism over its latest clinical trial progress.

What Traders Need To Know

  • H.C. Wainwright started coverage with a Buy rating and a $12 price target, signaling renewed Street attention on Relmada Therapeutics Inc.
  • NDV-01, a sustained-release intravesical chemotherapy for non-muscle invasive bladder cancer, is highlighted as a next-generation delivery platform.
  • The new Buy call lines up with an already bullish analyst view, with average targets around $12.67, well above current RLMD trading levels.
  • Recent price action shows RLMD holding above $6.40 and closing near intraday highs, hinting at buyers stepping in on positive news.

Candlestick Chart

Weekly Update Jun 22 – Jun 26, 2026: On Friday, June 26, 2026 Relmada Therapeutics Inc. stock [NASDAQ: RLMD] is trending up by 3.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Relmada Therapeutics (RLMD) is an early-stage biotech with no commercial revenue, structurally negative earnings, and heavy R&D burn. Recent quarterly net loss was ~$19.1M (EPS -$0.22) with operating cash burn of ~$15.1M, yielding ROE of roughly -49% and ROA around -45%, underscoring value-destructive economics. However, the balance sheet is clean: no debt, current ratio ~18x, and ~$234M in cash and equivalents versus an enterprise value near $14M, implying the market assigns minimal value to the pipeline.

Technically, RLMD has been trading in a tight, illiquid band this week between $6.45 and $6.89, with today’s action around $6.69 signaling modest recovery from recent lows but no established uptrend. The dominant pattern is sideways-to-down after prior weakness, with low volume and single-price prints indicating limited liquidity and higher slippage risk. The key actionable level is support near $6.40–6.45; a sustained close below that opens downside, while aggressive traders can define risk with tight stops just under $6.40.

Recent H.C. Wainwright initiation with a Buy rating and $12 target, focused on NDV-01, moves RLMD back onto institutional radar and supports a valuation re-rating toward the mid-teens if development progresses. Relative to broader Healthcare and Biotech indices, RLMD is far more speculative but significantly cash-backed. I view risk/reward as favorable with a 6–12 month upside target of $10–12, key resistance at $7.50 then $9.00, and strong support at $6.40.

More Breaking News

Quick Financial Overview

Relmada Therapeutics Inc. (RLMD) is trading in the mid-$6 area while analysts are clustered near a $12–$12.67 target range. That gap matters. It tells traders the Street is modeling upside if the pipeline, especially NDV-01, delivers. Weekly data show RLMD stabilizing after a pullback, with closes between $6.45 and $6.89, suggesting a developing base rather than a stock in free fall.

Intraday on 2026/06/26, RLMD opened near $6.40 in premarket, flushed early to around $6.39–$6.48, then trended higher most of the day. The stock pushed into the $6.80–$6.90 zone by midday, pulled back, and then closed at $6.69 near the top of the late-day range. That pattern — morning dip, steady grind up, close near highs — often signals accumulation and short-term momentum favoring the upside.

Financially, Relmada Therapeutics Inc. is still a development-stage biotech. Q1 2026 data show no revenue and a net loss of about $19.05M, with operating cash burn around $15.07M. Yet the balance sheet lists roughly $233.96M in cash and short-term investments and working capital of about $222.45M. Current and quick ratios above 18 show RLMD is well-capitalized with no long-term debt, though returns on equity and assets are deeply negative, reflecting heavy R&D and G&A spend without product sales yet.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”